Trial: 201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin
Expression Who Have Failed Standard Available Therapy



Principal Investigator

Opyrchal, Mateusz

Disease Site

Other Female Genital; Ovary; Pancreas

Learn more about this study at: